Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

NCT00034138 is registered in ClinicalTrials.gov with Unither Pharmaceuticals as lead sponsor.

NCT NCT00034138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Lead sponsor
Unither Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2002
Completion date
December 31, 2007
Enrollment
24
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms